Hims & Hers Health Inc. Stock News

Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.

Amazon's success expanding from books to cloud computing has set the benchmark for the ideal growth stock. By putting the customer first and being willing to take risks, Amazon tremendous wealth for investors.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.

Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuation reflects high growth expectations, leaving little room for missteps amid FDA scrutiny of compounded GLP-1 marketing and new tariff uncertainties. I'm expecting Hims & Hers to see near-term volati...

In this podcast, Motley Fool analysts Alicia Alfiere, Sanmeet Deo, and Tim Beyers discuss:

NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Hims & Hers Health, Inc.  (NYSE: HIMS)  breached their fiduciary duties to shareholders.

Hims & Hers Health (HIMS -3.07%) stock is soaring since I rated it a buy.

The financial market is a machine powered by shifting opinions, and when the Federal Reserve announced its latest interest rate cut, those opinions pushed capital into healthcare and financial stocks.